IDYA — IDEAYA Biosciences, Inc.

Is IDYA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

IDEAYA Biosciences, Inc. (IDYA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $38.87. The rating moved from Neutral to Overbought on August 6, 2026.

See all overbought Healthcare stocks →

AI analysis

IDEAYA Biosciences, Inc. (IDYA) is a development‑stage oncology company with a science‑driven pipeline focused on DNA damage response and synthetic‑lethality approaches. The stock is sensitive to binary clinical readouts and partnership news; favorable data or strategic deals could reprice shares higher, while trial setbacks or financing needs present meaningful downside. Given elevated sector M&A interest and selective growth appetite in the market, the near‑term trajectory will be driven by clinical progress, capital strategy, and headline flow.

Key factors

  • Pipeline focus on targeted oncology approaches (DNA damage response / synthetic‑lethality strategies) that can deliver high-value, binary clinical readouts
  • Potential near‑term clinical data or partnering/licensing announcements that could reprice the equity
  • Sector backdrop: elevated biotech/pharma M&A multiples that increase strategic acquiror interest in successful assets
  • Market environment showing selective interest in growth/biotech names despite overall balanced order flow
  • Differentiated scientific thesis with platform-level upside if lead programs show efficacy and acceptable safety
  • Limited public financial visibility in the short window increases sensitivity to news and funding events

Risks

  • Clinical trial binary risk — negative or delayed readouts would materially pressure the share price
  • Cash burn and financing risk — need to raise capital could cause dilution or unfavorable terms
  • Regulatory risk — uncertain timing and outcome of approvals for novel mechanisms
  • Competitive risk — other companies pursuing DDR, synthetic lethality, or alternative oncology modalities could limit commercial opportunity
  • Market/sector sentiment swings — biotech sector rotation or broader risk‑off moves can disproportionately impact small/mid‑cap biotechs
  • Partnership execution risk — setbacks or discontinuation of collaborations would reduce de‑risking paths
  • Payer/reimbursement uncertainty for oncology specialties could temper long‑term commercial expectations

See today's live rating, score and targets

Members see the live hourly rating for IDYA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.